From the last earnings call, revenue from milestones alone will be $45 million, plus approximately$35 million in Adectris sales for the quarter, plus collaboration $. Revenue should be in the $100+ million range, almost double analysts unadjusted expectations, despite the CFO hinting the following in the previous earnings call. Look for a blowout, as the number to beat is approximately $57 million:
"The fourth quarter of this will be particularly strong from a cash generation perspective. We expect to receive more than $100 million during the quarter which includes the $25 million Abbott collaboration payment, $25 million in approval milestone payments from Millennium, anticipated collections from ADCETRIS sales and other collaboration payments.
Fourth quarter collaboration revenues will reflect approximately $7.7 million related to the European approval milestones from Millennium and we will begin to amortize the $25 million Abbott payment over the two-year development term of the expanded collaboration...."